AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26374194 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's self-identified goals (n=18) using the Perceived Efficacy and Goal-Setting System
Number of subjects: 34
Study 26374194 — intervention group
Group type: COMPARATOR
Intervention: Goals identified by parents (n=16) using the Canadian Occupational Performance Measure (COPM)
Number of subjects: 34
Study 26374194 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups post-intervention
Number of subjects: 34
Study 24389521 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit resistance training (CRT) performed three times weekly for 40‐45 min each session with immediate protein supplementation (PS) of whey protein = 36‐37 g before and after exercise
Number of subjects: 11
Study 24389521 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit resistance training (CRT) performed three times weekly for 40‐45 min each session with delayed protein supplementation (PS) of matched protein dose 24 h postexercise
Number of subjects: 11
Study 22153143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training through yoga, 1 hour a week for 8 weeks, plus 10 minutes of daily homework
Number of subjects: 0
Study 22153143 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 20630302 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical negative pressure (ANP) irrigation
Number of subjects: 100
Study 20630302 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic (PUI) activation
Number of subjects: 100
Study 20630302 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoactivator (sonic activation)
Number of subjects: 100
Study 20630302 — intervention group
Group type: EXPERIMENTAL
Intervention: F file
Number of subjects: 100
Study 20630302 — intervention group
Group type: COMPARATOR
Intervention: Positive pressure irrigation (control group)
Number of subjects: 100
Study 18652112 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with modern rehabilitation techniques
Number of subjects: 60
Study 18652112 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation treatment only
Number of subjects: 60
Study 16236699 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient portal
Number of subjects: 606
Study 16236699 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 606
Study 12870876 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL Oil of Wintergreen
Number of subjects: 4
Study 12870876 — intervention group
Group type: COMPARATOR
Intervention: 6.7 g of Ben Gay 15%
Number of subjects: 4
Study 12870876 — intervention group
Group type: COMPARATOR
Intervention: 20 g of Ben Gay 15%
Number of subjects: 4
Study 12870876 — intervention group
Group type: COMPARATOR
Intervention: 5 g of Ben Gay 15% cream held in the buccal cavity for 1 minute and then expectorated
Number of subjects: 4
Study 10554538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite i.v. 1 mg bolus/2 x 1 mg infusion 1 day before ERCP
Number of subjects: 60
Study 10554538 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.5 g/ofloxacin 0.2 g before and 6 hours after ERCP
Number of subjects: 60
Study 10554538 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 60
Study 8919724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (500 mg orally every 6 hours for 3 days)
Number of subjects: 107
Study 8919724 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole orally every 12 hours for 3 days)
Number of subjects: 107
Study 31910835 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial social capital (family sense of belonging)
Number of subjects: 2068
Study 31910835 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial social capital (family autonomy support)
Number of subjects: 2068
Study 31910835 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial social capital (family control)
Number of subjects: 2068
Study 31910835 — intervention group
Group type: EXPERIMENTAL
Intervention: School social capital (school sense of belonging)
Number of subjects: 2068
Study 31910835 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status (SES)
Number of subjects: 2068
Study 31347994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quintile of GWG rate
Number of subjects: 14219
Study 31347994 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of GWG rate
Number of subjects: 14219
Study 27802927 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent with biodegradable polymer (BP-BES)
Number of subjects: 5942
Study 27802927 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent with durable polymer (DP-EES)
Number of subjects: 5942
Study 26194374 — intervention group
Group type: EXPERIMENTAL
Intervention: TSU-68 plus docetaxel
Number of subjects: 77
Study 26194374 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 77
Study 24399652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 23036875 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic visceral mobilisation of the sigmoid colon
Number of subjects: 15
Study 23036875 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 19248698 — intervention group
Group type: EXPERIMENTAL
Intervention: Omron HEM‐907 blood pressure measuring device
Number of subjects: 104
Study 16146617 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate 20 mg bid
Number of subjects: 12
Study 16146617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16146617 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate 100 mg daily for eight weeks
Number of subjects: 12
Study 12838196 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with DHA (0.36%) + ARA (0.72%)
Number of subjects: 61
Study 12838196 — intervention group
Group type: COMPARATOR
Intervention: Commercial formula
Number of subjects: 61
Study 11006368 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 38
Study 11006368 — intervention group
Group type: COMPARATOR
Intervention: Control (no growth hormone treatment)
Number of subjects: 38
Study 8708225 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush
Number of subjects: 2
Study 8708225 — intervention group
Group type: COMPARATOR
Intervention: Foam swabs
Number of subjects: 2
Study 1360714 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrisanolum (Chr)
Number of subjects: 126
Study 1360714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalicylic drugs (SSD)
Number of subjects: 126
Study 1360714 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MT)
Number of subjects: 126
Study 1360714 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (NSAID)
Number of subjects: 126
Study 3901360 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 milligrams of doxycycline preoperatively
Number of subjects: 51
Study 3901360 — intervention group
Group type: COMPARATOR
Intervention: 5 grams of cefamandole in four doses over a period of 18 hours
Number of subjects: 51
Study 31509204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced implementation approach (coaching, collaborative peer learning, and peer comparison feedback)
Number of subjects: 20
Study 31509204 — intervention group
Group type: COMPARATOR
Intervention: Usual implementation approach
Number of subjects: 20
Study 31509204 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement toolkit
Number of subjects: 20
Study 29303840 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care
Number of subjects: 0
Study 29303840 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care interventions delivered by an interdisciplinary team
Number of subjects: 0
Study 27518403 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α2b spray
Number of subjects: 400
Study 27518403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 25218597 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 76
Study 25218597 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 76
Study 25218597 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 76
Study 22118328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac revascularization
Number of subjects: 52
Study 22118328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac revascularization (responders)
Number of subjects: 52
Study 20177797 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with breast cancer (group B, n = 18)
Number of subjects: 35
Study 20177797 — intervention group
Group type: COMPARATOR
Intervention: Women without breast cancer (group A, n = 17)
Number of subjects: 35
Study 17917469 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 psychotherapeutic sessions based on the modified reattribution model
Number of subjects: 91
Study 17917469 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational reading material
Number of subjects: 91
Study 15771333 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional medium-hard toothbrush 'Pingu'
Number of subjects: 47
Study 15771333 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional soft toothbrush 'CuraKid'
Number of subjects: 47
Study 15771333 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-headed toothbrush 'Superbrush'
Number of subjects: 47
Study 15771333 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study 12742300 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 5000
Study 10096928 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg/d for 3 days, then 500 mg/wk for 3 months)
Number of subjects: 302
Study 10096928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 10096928 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 302
Study 9735596 — intervention group
Group type: EXPERIMENTAL
Intervention: Key size of 6 mm
Number of subjects: 9
Study 9735596 — intervention group
Group type: EXPERIMENTAL
Intervention: Key size of 12 mm
Number of subjects: 9
Study 9735596 — intervention group
Group type: EXPERIMENTAL
Intervention: Key size of 21 mm
Number of subjects: 9
Study 9735596 — intervention group
Group type: EXPERIMENTAL
Intervention: Key size of 30 mm
Number of subjects: 9
Study 9735596 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-key spacing of 3 mm
Number of subjects: 9
Study 9735596 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-key spacing of 0 mm
Number of subjects: 9
Study 9735596 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-key spacing of 3, 6, and 12 mm
Number of subjects: 9
Study 1867419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atropine (0.02 mg/kg)
Number of subjects: 90
Study 1867419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glycopyrrolate (0.05 mg/kg)
Number of subjects: 90
Study 1867419 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 90
Study 6617931 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of L-carnitine
Number of subjects: 12
Study 6617931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28604135 — intervention group
Group type: EXPERIMENTAL
Intervention: SOY+RT (25 g of soy protein with resistance training)
Number of subjects: 32
Study 28604135 — intervention group
Group type: COMPARATOR
Intervention: PL+RT (25 g of maltodextrin placebo with resistance training)
Number of subjects: 32
Study 27090817 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein glycomacropeptide (CGMP) 30 g daily
Number of subjects: 24
Study 27090817 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (4800 mg oral mesalamine daily)
Number of subjects: 24
Study 25148789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.3 mg
Number of subjects: 759
Study 25148789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg
Number of subjects: 759
Study 25148789 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 759
Study 22792813 — intervention group
Group type: EXPERIMENTAL
Intervention: Double fill nine tastes soup, water frying points 2 times orally, for 2 months
Number of subjects: 77
Study 22792813 — intervention group
Group type: COMPARATOR
Intervention: Transfer factor oral liquid, 10 mL, 2 times daily orally, for 2 months
Number of subjects: 77
Study 19725893 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone 50/100 microg BD via Diskus
Number of subjects: 42
Study 19725893 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone 100 microg BD via Diskus
Number of subjects: 42
Study 19725893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 18670224 — intervention group
Group type: EXPERIMENTAL
Intervention: In utero exposure to maternal HAART
Number of subjects: 0
Study 18670224 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine exposure
Number of subjects: 0
Study 18670224 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal exposure to HAART
Number of subjects: 0
Study 15702295 — intervention group
Group type: EXPERIMENTAL
Intervention: Photons (60 Gy, 30 fractions; 8 MV, (60)Co)
Number of subjects: 27
Study 15702295 — intervention group
Group type: COMPARATOR
Intervention: Neutrons (18 Gy, twelve fractions; 66 MeV(p‐‐>Be))
Number of subjects: 27
Study 12957267 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular brachytherapy (VBT) with a (90)Sr/(90)Y source, prescribed dose at 2 mm from the centerline of the source axis was 18.4 Gy or 23 Gy
Number of subjects: 204
Study 12957267 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular brachytherapy (VBT) with a (90)Sr/(90)Y source
Number of subjects: 204
Study 12957267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 11106135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline-Continuation
Number of subjects: 50
Study 11106135 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Switch
Number of subjects: 50
Study 11106135 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Responder
Number of subjects: 50
Study 8852770 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium‐Mucofalk
Number of subjects: 40
Study 8852770 — intervention group
Group type: COMPARATOR
Intervention: Barium‐methylcellulose
Number of subjects: 40
Study 1387767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 29
Study 1387767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 29
Study 1387767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 6329547 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg enalapril twice daily (n = 18)
Number of subjects: 36
Study 6329547 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 36
Study 31272495 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with quarterly clinic visits
Number of subjects: 495
Study 31272495 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIVST with biannual clinic visits plus oral HIVSTs
Number of subjects: 495
Study 31272495 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based HIVST with biannual clinic visits plus blood-based HIVSTs
Number of subjects: 495
Study 31252222 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (M1 receptor antagonist, 4 mg)
Number of subjects: 30
Study 31252222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28552878 — intervention group
Group type: EXPERIMENTAL
Intervention: LD+MCT (L-leucine 1.2 g, cholecalciferol 20 μg, 6 g of MCT)
Number of subjects: 38
Study 28552878 — intervention group
Group type: EXPERIMENTAL
Intervention: LD+LCT (L-leucine 1.2 g, cholecalciferol 20 μg, 6 g of long-chain triglycerides)
Number of subjects: 38
Study 28552878 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 38
Study 25905714 — intervention group
Group type: EXPERIMENTAL
Intervention: 45° elevated upper body position
Number of subjects: 55
Study 25905714 — intervention group
Group type: COMPARATOR
Intervention: Nonelevated position
Number of subjects: 55
Study 25905714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 55
Study 24330691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (phosphodiesterase 5 inhibitor) administered daily for a short term (duration not specified)
Number of subjects: 0
Study 21554816 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g α-cyclodextrin
Number of subjects: 10
Study 18277121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 0
Study 18277121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 0
Study 17137978 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherical IOL (Tecnis Z9000)
Number of subjects: 20
Study 17137978 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOL (Sensar AR40e)
Number of subjects: 20
Study 17137978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 20
Study 12626865 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 100
Study 12626865 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine analgesia
Number of subjects: 100
Study 11065083 — intervention group
Group type: EXPERIMENTAL
Intervention: BFHI training of medical, midwifery, and nursing staffs (experimental group)
Number of subjects: 17795
Study 11065083 — intervention group
Group type: COMPARATOR
Intervention: Routine practices (control group)
Number of subjects: 17795
Study 9056052 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-462
Number of subjects: 16
Study 9056052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 16
Study 8396099 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day, single dose for three days)
Number of subjects: 159
Study 8396099 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (tid for ten days, dosage according to manufacturer's instructions)
Number of subjects: 159
Study 3002707 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (60 mg daily for 7 days)
Number of subjects: 0
Study 3002707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28857461 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3127760
Number of subjects: 13
Study 28857461 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg)
Number of subjects: 13
Study 28857461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 26948252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous frusemide and enteral indapamide (Group F + I)
Number of subjects: 40
Study 26948252 — intervention group
Group type: COMPARATOR
Intervention: Intravenous frusemide (Group F)
Number of subjects: 40
Study 24499394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy (CBT)
Number of subjects: 26
Study 24499394 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation group programme (EDUC)
Number of subjects: 26
Study 22357522 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBV)
Number of subjects: 10
Study 22357522 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 20179318 — intervention group
Group type: EXPERIMENTAL
Intervention: Minorities perceived as expert
Number of subjects: 0
Study 20179318 — intervention group
Group type: COMPARATOR
Intervention: Minorities not perceived as expert
Number of subjects: 0
Study 20179318 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority members' deeper processing
Number of subjects: 0
Study 17823938 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on 6 variables (age, heart rate, Glasgow Coma Scale score, cranial nerve palsies, cerebrospinal fluid leukocyte count < 1,000 cells/mm3, gram-positive cocci in cerebrospinal fluid Gram's stain)
Number of subjects: 696
Study 17823938 — intervention group
Group type: COMPARATOR
Intervention: Risk score validation in the European Dexamethasone Study
Number of subjects: 696
Study 15795549 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0
Study 12848392 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (60 g x day(-1))
Number of subjects: 51
Study 12848392 — intervention group
Group type: COMPARATOR
Intervention: Whey protein powder
Number of subjects: 51
Study 10594483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantofarone 100 mg
Number of subjects: 6
Study 10594483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantofarone 300 mg
Number of subjects: 6
Study 10594483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8546738 — intervention group
Group type: EXPERIMENTAL
Intervention: cM‐T412 monoclonal antibody, 50 mg/day for 5 days, followed by 50 mg/week for 5 weeks (6 patients) or retreatment of 50 mg/day for 5 days after 5 weeks (6 patients)
Number of subjects: 12
Study 1986287 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of cyclosporine per kilogram per day
Number of subjects: 85
Study 1986287 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of cyclosporine per kilogram per day
Number of subjects: 85
Study 1986287 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of cyclosporine per kilogram per day
Number of subjects: 85
Study 1986287 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 85
Study 7423283 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 4.5 mg in the form of 0.5 mg oral tablets
Number of subjects: 22
Study 7423283 — intervention group
Group type: COMPARATOR
Intervention: PGE2 4.5 mg in the form of tylose gel
Number of subjects: 22
Study 30481495 — intervention group
Group type: EXPERIMENTAL
Intervention: Online care
Number of subjects: 296
Study 30481495 — intervention group
Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 296
Study 27734072 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet microparticle assay (PMA)
Number of subjects: 401